Regular liver function tests are recommended during treatment.Cardiovascular Risks: It can affect cholesterol levels (increasing LDL and decreasing HDL), which may raise the risk of atherosclerosis and coronary artery disease
GLOW Peptide Regulatory Status As of June 2026, none of the three GLOW compounds (BPC-157, TB-500, GHK-Cu) are FDA-approved for injectable human use
Usage and Safety Disclaimers Consultation with Healthcare Provider: Consult your healthcare provider before using this product if you are pregnant, nursing, taking any medications, or have any medical conditions
The regulatory landscape governing compounded medications is subject to change
Accessed February 5, 2018.
[20] Symptoms occur differently for each person, and can include trouble walking or moving in general